Sang Beom Kim

Sang Beom Kim


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
YKYoung Nam Kwon
Young Nam Kwon
BKBoram Kim
Boram Kim
JKJun-Soon Kim
Jun-Soon Kim
HMHeejung Mo
Heejung Mo
KCKyomin Choi
Kyomin Choi
SKSung-Min Kim
Sung-Min Kim
Background and Objective To investigate the clinical relevance of CSF myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) testing in a large multicenter cohort. Methods In this multicenter cohort study, paired serum-CSF samples from 474 patients with suspected inflammatory demyelinating disease (IDD) from 11 referral hospitals were included. After serum screening, patients were grouped into seropositive myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD, 31), aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD, 60), other IDDs (217), multiple sclerosis (MS, 45), and non-IDDs (121). We then screened CSF for MOG-IgG and compared the clinical and serologic characteristics of patients uniquely positive for MOG-IgG in the CSF to seropositive patients with MOGAD. Results Nineteen patients with seropositive MOGAD (61.3%), 9 with other IDDs (CSF MOG + IDD, 4.1%), 4 with MS (8.9%), but none with AQP4-IgG + NMOSD nor with non-IDDs tested positive in the CSF for MOG-IgG. The clinical, pathologic, and prognostic features of patients uniquely positive for CSF MOG-IgG, with a non-MS phenotype, were comparable with those of seropositive MOGAD. Intrathecal MOG-IgG synthesis, observed from the onset of disease, was shown in 12 patients: 4 of 28 who were seropositive and 8 who were uniquely CSF positive, all of whom had involvement of either brain or spinal cord. Both CSF MOG-IgG titer and corrected CSF/serum MOG-IgG index, but not serum MOG-IgG titer, were associated with disability, CSF pleocytosis, and level of CSF proteins. Discussion CSF MOG-IgG is found in IDD other than MS and also in MS. In IDD other than MS, the CSF MOG-IgG positivity can support the diagnosis of MOGAD. The synthesis of MOG-IgG in the CNS of patients with MOGAD can be detected from the onset of the disease and is associated with the severity of the disease. Classification of Evidence This study provides Class II evidence that the presence of CSF MOG-IgG can improve the diagnosis of MOGAD in the absence of an MS phenotype, and intrathecal synthesis of MOG-IgG was associated with increased disability.

8 July 2022 in Genes
Verified
Journal Article
Open access
PDF file
NJNa Young Jung
Na Young Jung
Hye Mi KwonHye Mi Kwon
Hye Mi Kwon
DNDa Nam
Da Nam
NTNasrin Tamanna
Nasrin Tamanna
ALAh Jin Lee
Ah Jin Lee
KCKi Wha Chung
Ki Wha Chung
Duplication and deletion of the peripheral myelin protein 22 (PMP22) gene cause Charcot-Marie-Tooth disease type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP), respectively, while point mutations or small insertions and deletions (indels) usually cause CMT type 1E (CMT1E) or HNPP. This study was performed to identify PMP22 mutations and to analyze the genotype–phenotype correlation in Korean CMT families. By the application of whole-exome sequencing (WES) and targeted gene panel sequencing (TS), we identified 14 pathogenic or likely pathogenic PMP22 mutations in 21 families out of 850 CMT families who were negative for 17p12 (PMP22) duplication. Most mutations were located in the well-conserved transmembrane domains. Of these, eight mutations were not reported in other populations. High frequencies of de novo mutations were observed, and the mutation sites of c.68C>G and c.215C>T were suggested as the mutational hotspots. Affected individuals showed an early onset-severe phenotype and late onset-mild phenotype, and more than 40% of the CMT1E patients showed hearing loss. Physical and electrophysiological symptoms of the CMT1E patients were more severely damaged than those of CMT1A while similar to CMT1B caused by MPZ mutations. Our results will be useful for the reference data of Korean CMT1E and the molecular diagnosis of CMT1 with or without hearing loss.

1 January 2021 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
HKHyun Su Kim
Hyun Su Kim
HKHye Jin Kim
Hye Jin Kim
SNSoo Hyun Nam
Soo Hyun Nam
SKSang Beom Kim
Sang Beom Kim
YCYu Jin Choi
Yu Jin Choi
BCByung-Ok Choi
Byung-Ok Choi
Kim HS, et al. J Clin Neurol. 2021 Jan;17(1):52-62. https://doi.org/10.3988/jcn.2021.17.1.52

23 November 2021 in Journal of the Peripheral Nervous System
Verified
Journal Article
Closed access
PDF file
DNDa Eun Nam
Da Eun Nam
JPJin Hee Park
Jin Hee Park
CPCho Eun Park
Cho Eun Park
NJNa Young Jung
Na Young Jung
SNSoo Hyun Nam
Soo Hyun Nam
KCKi Wha Chung
Ki Wha Chung

31 December 2018 in Journal of Neurosonology and Neuroimaging
Verified
Journal Article
Open access
PDF file
SLSeung-Jae Lee
Seung-Jae Lee
SYSungwook Yu
Sungwook Yu
JHJi Man Hong
Ji Man Hong
SASeong Hwan Ahn
Seong Hwan Ahn
SJSeul-Ki Jeong
Seul-Ki Jeong
HSHEE-JUNG SONG
HEE-JUNG SONG

28 May 2021 in Life
Verified
Journal Article
Open access
PDF file
Hye Mi KwonHye Mi Kwon
Hye Mi Kwon
HKHyun Su Kim
Hyun Su Kim
SKSang Beom Kim
Sang Beom Kim
JPJae Hong Park
Jae Hong Park
DNDa Nam
Da Nam
BCByung-Ok Choi
Byung-Ok Choi
Charcot–Marie–Tooth disease (CMT) is the most common inherited peripheral neuropathy. Mutations in the GNB4 gene cause dominant intermediate CMT type F (CMTDIF). The aim of this study is to investigate phenotypic heterogeneities and characteristics of CMT patients with GNB4 mutations. We enrolled 1143 Korean CMT families and excluded 344 families with a PMP22 duplication. We further analyzed the 799 remaining families to find their GNB4 mutations using whole-exome sequencing (WES). We identified two mutations (p.Gly77Arg and p.Lys89Glu) in three families, among which a heterozygous p.Gly77Arg mutation was novel. In addition, a significant uncertain variant (p.Thr177Asn) was observed in one family. The frequency of the GNB4 mutation in the Korean population is 0.38% in PMP22 duplication-negative families. All three families showed de novo mutation. Electrophysiological findings regarding the p.Lys89Glu mutation showed that the motor nerve conduction velocity (MNCV) of the median nerve was markedly reduced, indicating demyelinating neuropathy, and sural nerve biopsy revealed severe loss of myelinated axons with onion bulb formation. Lower extremity Magnetic Resonance Imaging (MRI) demonstrated relatively more severe intramuscular fat infiltrations in demyelinating type (p.Lys89Glu mutation) patients compared to intermediate type (p.Gly77Arg mutation) patients. The anterolateral and superficial posterior compartment muscles of the distal calf were preferentially affected in demyelinating type patients. Therefore, it seems that the investigated GNB4 mutations do cause not only the known intermediate type but also demyelinating-type neuropathy. We first presented three Korean families with GNB4 mutations and found phenotypic heterogeneities of both intermediate and demyelinating neuropathy. We suggest that those findings are useful for the differential diagnosis of CMT patients with unknown GNB4 variants.